Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain

Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain

Our drug discovery model has identified two novel STAT3 SH2 domain inhibitors 323–1 and 323–2 (delavatine A stereoisomers) in a series of experiments. In silico computational modeling, drug affinity responsive target stability (DARTS), and fluorescence polarization (FP) assays altogether determined...

Full description

Bibliographic Details
Main Authors: Yaping Hua, Xing Yuan, Yun-heng Shen, Jinxin Wang, Waqas Azeem, Shuo Yang, Alexandra Gade, Seyed Mohammad Lellahi, Anne Margrete Øyan, Xisong Ke, Wei-dong Zhang, Karl-Henning Kalland
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Pharmacology
Subjects:
delavatine A
STAT3
SH2 domain
dimerization
prostate cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.836724/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.836724/full

Similar Items